Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Reistone Biopharma is a clinical-stage biopharmaceutical company focused on developing novel medicines for autoimmune and inflammatory diseases. With a mission to address unmet medical needs, Reistone leverages its global research and development capabilities to advance a pipeline of innovative therapies. The company integrates discovery, development, and commercialization efforts, with a strong emphasis on scientific rigor and patient outcomes.
Serves as the global research and development hub, overseeing drug discovery, preclinical research, early clinical development, and corporate strategy for the China region.
Located in Zhangjiang Hi-Tech Park, a leading life sciences cluster, featuring modern laboratory and office spaces designed for collaborative research and innovation.
A dynamic and innovative environment focused on scientific excellence, patient-centricity, and collaborative teamwork to advance biopharmaceutical breakthroughs. Emphasis on global standards and agile R&D processes.
The Shanghai headquarters is pivotal for Reistone's global R&D pipeline, driving innovation from discovery to early clinical phases and leveraging the rich talent pool and infrastructure of the Zhangjiang biotech ecosystem.
Reistone Biopharma supports its R&D and clinical operations globally, with primary centers in China (Shanghai and Beijing) and the United States (Greater Boston Area). The company conducts multinational clinical trials and aims to bring its innovative therapies for autoimmune and inflammatory diseases to patients worldwide by collaborating with international partners and regulatory agencies.
Building 10, Lane 666, Gaoke Middle Road, Zhangjiang Hi-Tech Park, Pudong New Area
Shanghai
Shanghai
China
Address: 200 Staples Drive, Suite 201, Framingham, MA 01702, USA
To advance Reistone's clinical pipeline in the United States, engage with regulatory authorities like the FDA, and foster partnerships within the North American biopharma ecosystem.
Address: Room 1601-1603, Block B, Topliš-China World Office Building, No. 1 Jianguomenwai Avenue, Chaoyang District, Beijing, China 100004
To manage and execute clinical trials effectively in China, navigate the local regulatory landscape, and prepare for potential commercialization of approved therapies in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Reistone Biopharma' leadership includes:
Reistone Biopharma has been backed by several prominent investors over the years, including:
In the past 12 months, Reistone Biopharma has strengthened its executive leadership, notably with the appointment of a new Chief Medical Officer to spearhead its global clinical development strategies. Publicly available information does not indicate major executive departures during this period.
Discover the tools Reistone Biopharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Reistone Biopharma likely utilizes common corporate email formats based on employee names and their domain 'reistonebio.com'. While not publicly confirmed, patterns such as [firstinitial][lastname] or [firstname].[lastname] are standard.
[firstinitial][lastname]@reistonebio.com
Format
mzhang@reistonebio.com
Example
85%
Success rate
PR Newswire / Company Website • February 26, 2024
Reistone Biopharma announced the appointment of Dr. Aik Hong Tan as its Chief Medical Officer. Dr. Tan will be responsible for leading the global clinical strategy and development of the company's innovative pipeline....more
Company Website • July 12, 2023
Reistone Biopharma announced that the first patient has been dosed in its Phase II clinical trial of SHR0302 (ivarmacitinib), a highly selective JAK1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in China....more
Company Website / PR Newswire • March 20, 2023
Reistone Biopharma's partner, Kaken Pharmaceutical Co., Ltd., announced that it has obtained manufacturing and marketing approval in Japan for EBGLYSS® for subcutaneous injection (lebrikizumab), an anti-IL-13 monoclonal antibody, for the treatment of atopic dermatitis. Reistone has the rights to develop and commercialize lebrikizumab in Greater China....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Reistone Biopharma, are just a search away.